Isoniazid plus antiretroviral therapy to prevent tuberculosis: A randomised double-blind, placebo-controlled trial

The Lancet

Volumn 384, Issue 9944, 2014, Pages 682-690

  Rangaka, Molebogeng X ^a,b   Wilkinson, Robert J ^a,c,d   Boulle, Andrew ^a   Glynn, Judith R ^b   Fielding, Katherine ^b   Van Cutsem, Gilles ^a,e   Wilkinson, Katalin A ^a   Goliath, Rene ^a   Mathee, Shaheed ^f   Goemaere, Eric ^e   Maartens, Gary ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^e MÉDECINS SANS FRONTIÈRES   (Switzerland)

^f WESTERN CAPE DEPARTMENT OF AGRICULTURE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; DIDANOSINE; EFAVIRENZ; ISONIAZID; LOPINAVIR PLUS RITONAVIR; PLACEBO; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIBIOTIC AGENT; PYRIDOXINE; QUINOLONE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALGORITHM; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; INFECTION RISK; INTENTION TO TREAT ANALYSIS; INTERFERON GAMMA RELEASE ASSAY; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; PERIPHERAL NEUROPATHY; PHARMACY; PHYSICIAN; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SOUTH AFRICA; SPUTUM CULTURE; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS; VIRUS LOAD; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; OUTCOME ASSESSMENT; RASH; SIDE EFFECT; TOXIC HEPATITIS; TUBERCULOSIS CONTROL;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; ISONIAZID; MALE; PLACEBOS; SOUTH AFRICA; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84906903227     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60162-8     Document Type: Article

References (36)

1. WHO WHO report 2011 global tuberculosis control http://www.who.int/tb/ publications/global-report/2011/gtbr11-full.pdf (accessed Jan 31, 2014).
2. C Akolo, I Adetifa, S Shepperd, J Volmink Treatment of latent tuberculosis infection in HIV infected persons Cochrane Database Syst Rev 1 2010 CD000171
3. AB Suthar, SD Lawn, J Del Amo et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis PLoS Med 9 2012 e1001270
4. A Gupta, R Wood, R Kaplan, LG Bekker, SD Lawn Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community PLoS One 7 2012 e34156
5. L Fenner, M Forster, A Boulle et al. Tuberculosis in HIV programmes in lower-income countries: practices and risk factors Int J Tuberc Lung Dis 15 2011 620 627
6. JE Golub, P Pronyk, L Mohapi et al. Isoniazid preventive therapy, HAantiretroviral therapy and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort AIDS 23 2009 631 636
7. JE Golub, V Saraceni, SC Cavalcante et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil AIDS 21 2007 1441 1448
8. T Samandari, TB Agizew, S Nyirenda et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial Lancet 377 2011 1588 1598
9. S Swaminathan, PA Menon, N Gopalan et al. Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial PLoS One 7 2012 e47400
10. X Wen, JS Wang, PJ Neuvonen, JT Backman Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes Eur J Clin Pharmacol 57 2002 799 804
11. MX Rangaka, RJ Wilkinson, JR Glynn et al. Effect of antiretroviral therapy on the diagnostic accuracy of symptom screening for intensified tuberculosis case finding in a South African HIV clinic Clin Infect Dis 55 2012 1698 1706
12. AIDS Clinical Trials Group Division of AIDS table for grading the everity of adult and pediatric adverse events http://www.niaid.nih.gov/ LabsAndResources/resources/DAIDSClinRsrch/Documents/daidsaegradingtable.pdf December, 2004
13. MX Rangaka, HP Gideon, KA Wilkinson et al. Interferon release does not add discriminatory value to smear-negative HIV-tuberculosis algorithms Eur Respir J 39 2012 163 171
14. M Zwarenstein, S Treweek, JJ Gagnier et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement BMJ 337 2008 a2390
15. JM Lachin, MA Foulkes Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification Biometrics 42 1986 507 519
16. E Lakatos, KK Lan A comparison of sample size methods for the logrank statistic Stat Med 11 1992 179 191
17. NA Martinson, GL Barnes, LH Moulton et al. New regimens to prevent tuberculosis in adults with HIV infection N Engl J Med 365 2011 11 20
18. B Durovni, V Saraceni, LH Moulton et al. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial Lancet Infect Dis 13 2013 852 858
19. WHO UNICEF UNAIDS Global update on HIV treatment 2013: results, impact and opportunities http://www.who.int/hiv/pub/progressreports/update2013/en/ June, 2013 (accessed Jan 31, 2014).
20. SH Ferebee Controlled chemoprophylaxis trials in tuberculosis. A general review Bibl Tuberc 26 1970 28 106
21. MA Quigley, A Mwinga, M Hosp et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults AIDS 15 2001 215 222
22. JL Johnson, A Okwera, DL Hom et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults AIDS 15 2001 2137 2147
23. WHO Stop TB Department Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings http://whqlibdoc.who.int/publications/2011/ 9789241500708-eng.pdf (accessed Jan 31, 2014).
24. MX Rangaka, KA Wilkinson, R Seldon et al. Effect of HIV-1 infection on T-cell-based and skin test detection of tuberculosis infection Am J Respir Crit Care Med 175 2007 514 520
25. KA Wilkinson, OM Kon, SM Newton et al. Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens J Infect Dis 193 2006 354 359
26. BJ Kirenga, W Worodria, M Massinga-Loembe et al. Tuberculin skin test conversion among HIV patients on antiretroviral therapy in Uganda Int J Tuberc Lung Dis 17 2013 336 341
27. A Zwerling, S van den Hof, J Scholten, F Cobelens, D Menzies, M Pai Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review Thorax 67 2012 62 70
28. M Pai, R O'Brien Serial testing for tuberculosis: can we make sense of T cell assay conversions and reversions? PLoS Med 4 2007 e208
29. JH Elliott, K Vohith, S Saramony et al. Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy J Infect Dis 200 2009 1736 1745
30. TL Fisk, HM Hon, JL Lennox, C Fordham von Reyn, CR Horsburgh Jr Detection of latent tuberculosis among HIV-infected patients after initiation of highly active antiretroviral therapy AIDS 17 2003 1102 1104
31. M Narita, D Ashkin, ES Hollender, AE Pitchenik Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS Am J Respir Crit Care Med 158 1998 157 161
32. Boulle A, Zweigental V, Hildebrand K, Magwaca N, Coetzee D. Incidence of tuberculosis pre- and post-antiretroviral therapy in a setting of high tuberculosis-HIV comorbidity. 15th International AIDS Conference; Bangkok, Thailand; July 11-16, 2004. 3239.
33. SD Lawn, L Myer, LG Bekker, R Wood Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control AIDS 20 2006 1605 1612
34. SD Lawn, K Kranzer, DJ Edwards, M McNally, LG Bekker, R Wood Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy AIDS 24 2010 1323 1328
35. A Boulle, G Van Cutsem, K Hilderbrand et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa AIDS 24 2010 563 572
36. MW Brinkhof, M Egger, A Boulle et al. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries Clin Infect Dis 45 2007 1518 1521